Clinical Trial Update: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors [Phase 2]

View source ↗

Summary

This phase 2 trial update investigates nivolumab with docetaxel and androgen deprivation therapy in men with hormone-sensitive or metastatic prostate cancer; th…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Adenocarcinoma
• Prostate Cancer

Drugs mentioned

• Androgen deprivation therapy (Androgen deprivation therapy)
• DOCETAXEL (DOCETAXEL)
• nivolumab (nivolumab)

Snippet

Sponsor: Xiao X. Wei, MD | Conditions: Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING